- Home
- FTLF vs NTHI Comparison
FTLF vs NTHI Comparison
Compare FTLF & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTLF | NTHI |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 114.6M |
| IPO Year | 2006 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FTLF | NTHI |
|---|---|---|
| Price | $9.73 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $21.50 | $15.00 |
| AVG Volume (30 Days) | 10.6K | ★ 108.0K |
| Earning Date | 05-14-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $21,744,000.00 | $39,990.00 |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $57.06 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $8.67 | $3.01 |
| 52 Week High | $20.98 | $12.99 |
Technical Indicators
Market Signals| Indicator | FTLF | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 52.37 |
| Support Level | $9.47 | $3.01 |
| Resistance Level | $12.55 | $4.59 |
| Average True Range (ATR) | 0.45 | 0.31 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 41.63 | 40.97 |
Price Performance
Historical ComparisonAbout FTLF FitLife Brands Inc.
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.